PMC:7534795 / 62648-63906 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T252","span":{"begin":769,"end":775},"obj":"Body_part"},{"id":"T253","span":{"begin":1069,"end":1076},"obj":"Body_part"},{"id":"T254","span":{"begin":1082,"end":1093},"obj":"Body_part"},{"id":"T255","span":{"begin":1102,"end":1119},"obj":"Body_part"},{"id":"T256","span":{"begin":1116,"end":1119},"obj":"Body_part"},{"id":"T257","span":{"begin":1144,"end":1154},"obj":"Body_part"}],"attributes":[{"id":"A252","pred":"fma_id","subj":"T252","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A253","pred":"fma_id","subj":"T253","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A254","pred":"fma_id","subj":"T254","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A255","pred":"fma_id","subj":"T255","obj":"http://purl.org/sig/ont/fma/fma67199"},{"id":"A256","pred":"fma_id","subj":"T256","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A257","pred":"fma_id","subj":"T257","obj":"http://purl.org/sig/ont/fma/fma82738"}],"text":"Fig. 2 Potential cardioprotective mechanisms of n-3 PUFAs in the setting of COVID-19. (A) N-3 PUFAs ameliorate uncontrolled immune responses and exert anti-inflammatory effects via several mechanisms. (B) N-3 PUFAs attenuate the vicious cycle/interaction of mitochondrial dysfunction and aggravated immune response. (C) N-3 PUFAs have the capability to attenuate viral infections via both direct effects on membrane integrity and indirect mechanisms through activating the humoral response to decrease overall viral load. (D) N-3 PUFAs have the ability to regulate the RAAS system in the favor of the vasodilatory, the anti-inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T90","span":{"begin":769,"end":775},"obj":"Body_part"}],"attributes":[{"id":"A90","pred":"uberon_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Fig. 2 Potential cardioprotective mechanisms of n-3 PUFAs in the setting of COVID-19. (A) N-3 PUFAs ameliorate uncontrolled immune responses and exert anti-inflammatory effects via several mechanisms. (B) N-3 PUFAs attenuate the vicious cycle/interaction of mitochondrial dysfunction and aggravated immune response. (C) N-3 PUFAs have the capability to attenuate viral infections via both direct effects on membrane integrity and indirect mechanisms through activating the humoral response to decrease overall viral load. (D) N-3 PUFAs have the ability to regulate the RAAS system in the favor of the vasodilatory, the anti-inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T425","span":{"begin":76,"end":84},"obj":"Disease"},{"id":"T426","span":{"begin":363,"end":379},"obj":"Disease"},{"id":"T427","span":{"begin":802,"end":814},"obj":"Disease"},{"id":"T428","span":{"begin":950,"end":962},"obj":"Disease"},{"id":"T429","span":{"begin":989,"end":997},"obj":"Disease"},{"id":"T430","span":{"begin":1213,"end":1218},"obj":"Disease"}],"attributes":[{"id":"A425","pred":"mondo_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A426","pred":"mondo_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A427","pred":"mondo_id","subj":"T427","obj":"http://purl.obolibrary.org/obo/MONDO_0001531"},{"id":"A428","pred":"mondo_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A429","pred":"mondo_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A430","pred":"mondo_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"Fig. 2 Potential cardioprotective mechanisms of n-3 PUFAs in the setting of COVID-19. (A) N-3 PUFAs ameliorate uncontrolled immune responses and exert anti-inflammatory effects via several mechanisms. (B) N-3 PUFAs attenuate the vicious cycle/interaction of mitochondrial dysfunction and aggravated immune response. (C) N-3 PUFAs have the capability to attenuate viral infections via both direct effects on membrane integrity and indirect mechanisms through activating the humoral response to decrease overall viral load. (D) N-3 PUFAs have the ability to regulate the RAAS system in the favor of the vasodilatory, the anti-inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T374","span":{"begin":87,"end":88},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T375","span":{"begin":202,"end":203},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T376","span":{"begin":407,"end":415},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T377","span":{"begin":458,"end":468},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T378","span":{"begin":688,"end":693},"obj":"http://purl.obolibrary.org/obo/CLO_0037161"},{"id":"T379","span":{"begin":911,"end":912},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T380","span":{"begin":1213,"end":1240},"obj":"http://purl.obolibrary.org/obo/PR_000000134"}],"text":"Fig. 2 Potential cardioprotective mechanisms of n-3 PUFAs in the setting of COVID-19. (A) N-3 PUFAs ameliorate uncontrolled immune responses and exert anti-inflammatory effects via several mechanisms. (B) N-3 PUFAs attenuate the vicious cycle/interaction of mitochondrial dysfunction and aggravated immune response. (C) N-3 PUFAs have the capability to attenuate viral infections via both direct effects on membrane integrity and indirect mechanisms through activating the humoral response to decrease overall viral load. (D) N-3 PUFAs have the ability to regulate the RAAS system in the favor of the vasodilatory, the anti-inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane."}

LitCovid-PD-CHEBI

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T110","span":{"begin":124,"end":140},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T111","span":{"begin":299,"end":314},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T112","span":{"begin":363,"end":379},"obj":"http://purl.obolibrary.org/obo/GO_0016032"},{"id":"T113","span":{"begin":950,"end":962},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T114","span":{"begin":1219,"end":1227},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T115","span":{"begin":1219,"end":1227},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T116","span":{"begin":1219,"end":1227},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T117","span":{"begin":1219,"end":1227},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"Fig. 2 Potential cardioprotective mechanisms of n-3 PUFAs in the setting of COVID-19. (A) N-3 PUFAs ameliorate uncontrolled immune responses and exert anti-inflammatory effects via several mechanisms. (B) N-3 PUFAs attenuate the vicious cycle/interaction of mitochondrial dysfunction and aggravated immune response. (C) N-3 PUFAs have the capability to attenuate viral infections via both direct effects on membrane integrity and indirect mechanisms through activating the humoral response to decrease overall viral load. (D) N-3 PUFAs have the ability to regulate the RAAS system in the favor of the vasodilatory, the anti-inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T474","span":{"begin":0,"end":998},"obj":"Sentence"},{"id":"T475","span":{"begin":999,"end":1258},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Fig. 2 Potential cardioprotective mechanisms of n-3 PUFAs in the setting of COVID-19. (A) N-3 PUFAs ameliorate uncontrolled immune responses and exert anti-inflammatory effects via several mechanisms. (B) N-3 PUFAs attenuate the vicious cycle/interaction of mitochondrial dysfunction and aggravated immune response. (C) N-3 PUFAs have the capability to attenuate viral infections via both direct effects on membrane integrity and indirect mechanisms through activating the humoral response to decrease overall viral load. (D) N-3 PUFAs have the ability to regulate the RAAS system in the favor of the vasodilatory, the anti-inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T200","span":{"begin":258,"end":283},"obj":"Phenotype"},{"id":"T201","span":{"begin":745,"end":761},"obj":"Phenotype"},{"id":"T202","span":{"begin":802,"end":814},"obj":"Phenotype"},{"id":"T203","span":{"begin":1213,"end":1218},"obj":"Phenotype"}],"attributes":[{"id":"A200","pred":"hp_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/HP_0003287"},{"id":"A201","pred":"hp_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/HP_0025464"},{"id":"A202","pred":"hp_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/HP_0003256"},{"id":"A203","pred":"hp_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Fig. 2 Potential cardioprotective mechanisms of n-3 PUFAs in the setting of COVID-19. (A) N-3 PUFAs ameliorate uncontrolled immune responses and exert anti-inflammatory effects via several mechanisms. (B) N-3 PUFAs attenuate the vicious cycle/interaction of mitochondrial dysfunction and aggravated immune response. (C) N-3 PUFAs have the capability to attenuate viral infections via both direct effects on membrane integrity and indirect mechanisms through activating the humoral response to decrease overall viral load. (D) N-3 PUFAs have the ability to regulate the RAAS system in the favor of the vasodilatory, the anti-inflammatory and the cardioprotective ACE2/Ang (1–7) effectors. (E) N-3 PUFAs enhance antioxidant capacity and attenuate oxidative stress in the tissue. (F) N-3 PUFAs ameliorate coagulopathy by exerting anti-thrombotic effects. (G) The triglyceride-lowering effect of n-3 PUFAs may play a key role in blunting the exaggerated inflammation observed in patients with COVID-19. ACE, Angiotensin-converting enzyme; Ang, Angiotensin; CRP, C-reactive protein; IL, Interleukin; mtDNA, Mitochondrial DNA; PUFA, Poly unsaturated fatty acid; ROS, Reactive oxygen species; TGs, Triglycerides; TNF-α, Tumor necrosis factor alpha; TX, Thromboxane."}

LitCovid-PubTator

PMC:7534795 / 62648-63906 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7534795 / 62648-63906 JSON TXT